PDA

View Full Version : Neurodegeneration Research

  1. Kral, et al. (2002). Vertebral artery injury after cervical spine trauma: a prospective study.
  2. Kuhn, et al. (2003). The mouse MPTP model: gene expression changes in dopaminergic neurons.
  3. Becker, et al. (2002). Early diagnosis of Parkinson's disease.
  4. Tomimatsu, et al. (2003). Long-term neuroprotective effects of hypothermia on neonatal hypoxic-ischemic brain injury in rats, assessed by auditory brainstem response.
  5. • Lu, et al. (2002). Tyrosine phosphatase inhibition enhances neurotrophin potency and rescues nigrostriatal neurons in adult rats.
  6. Liu, et al. (2003). Close axonal injury of rubrospinal neurons induced transient perineuronal astrocytic and microglial reaction that coincided with their massive degeneration.
  7. Raineteau, et al. (2002). Reorganization of descending motor tracts in the rat spinal cord.
  8. Redmond (2002). Cellular replacement therapy for Parkinson's disease--where we are today?
  9. Ando, et al. (2003). Caspase-1 and -3 mRNAs are differentially upregulated in motor neurons and glial cells in mutant SOD1 transgenic mouse spinal cord: a study using laser microdissection and real-time RT-PCR.
  10. Polgar, et al. (2003). Reconstructive neurosurgery for Parkinson's disease: a systematic review and preliminary meta-analysis.
  11. Misiuta, et al. (2003). Can the developing striatum effect the dopaminergic features of hNT neurons in vitro?
  12. Selenium and selenoproteins in the brain and brain diseases
  13. Ikeda, et al. (2000). Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse.
  14. Bouhlel, et al. (2003). Nandrolone decanoate reduces changes induced by hindlimb suspension in voltage-dependent tension of rat soleus muscle.
  15. Vinci (2003). Gait rehabilitation in a patient affected with Charcot-Marie-Tooth disease associated with pyramidal and cerebellar features and blindness.
  16. Zhang, et al. (2003). Depletion of wild-type huntingtin in mouse models of neurologic diseases.
  17. Simpson, et al. (2003). Oxidative stress:... amyotrophic lateral sclerosis
  18. SYRINGOMELIA
  19. Gonzalez, et al. (2004). Progesterone increase BDNF and protects spinal motoneurons
  20. Zhang, et al. (2004). CNTF accelerates peripheral nerve regeneration
  21. Zeman, et al. (2004). Clenbuterol retards motor loss in motor degeneration mice
  22. Bergerot, et al. (2004). Cotreatment riluzole and GDNF for recovery after ventral root avulsion
  23. husband with als
  24. Bruce, et al. (2004) Chemotherapy Delays Progression of Motor Neuron Disease
  25. Silani, et al. (2004). Stem-cell therapy for amyotrophic lateral sclerosis.
  26. Raman, et al. (2004). Delayed disease progression in ALS mice by treatment with a cannabinoid.
  27. Meininger, et al. (2004). Xaliproden treatment of ALS (2 phase III trials)
  28. Azzouz, et al. (2004). VEGF gene transfection prolongs survival in mouse ALS model
  29. Di Lazzaro, et al. (2004). Motor cortex stimulation treatment of ALS
  30. Amtmann, et al. (2004). Survey of ALS use in ALS
  31. Kieran, et al. (2004). Arimoclomol, inducer of heat shock proteins, delays ALS progression in mice.
  32. Kirkinezos, et al. (2004). Cyclosprin treatment of ALS mouse with permeable blood-brain barrier
  33. Klivenyi, et al. (2004). Creatine and COX-2 inhibitor treatment of mouse ALS model
  34. Pamphlett, et al. (2003). Mg supplement does not improve ALS in mice
  35. Turner, et al. (2003). Clozapine effects of ALS mice
  36. Kimura, et al. (2003). 100 Japanese amyotrophic lateral sclerosis patients between 1980 and 2000
  37. Turner, et al. (2003). 5-hydroxy-tryptophan effects on ALS mice
  38. Norquist, et al. (2003). Predictors of health status in patients with ALS
  39. Pattee, et al. (2003). Pramipexole reduces oxidative stress in patients with ALS
  40. Miller, et al. (2003). Riluzole treatment of ALS
  41. Mazzini, et al. (2003). Bone marrow stem cell therapy of ALS
  42. Harper, et al. (2004). Axon growth of ESC motoneurons in culture and rats with motoneuron injury
  43. Garbuzova-Davis, et al. (2003). IV human umbilical blood treatment of mice with ALS
  44. Azzouz, Mazarakis (2004) Non-primate EIAV-based lentiviral vectors as gene delivery system
  45. Vincent, Mobley, Hiller, Feldman (2004) - IGF-I prevents glutamate-induced motor neuron programmed c
  46. Kaspar, et al. (2003) - Retrograde viral delivery of IGF-1 prolongs surviva
  47. Stem Cell
  48. Dr. Huang Hongyun - Contact details
  49. MND sufferer - lady 57 yrs old
  50. Rare disease research
  51. Study finds IV drug use ages young brains
  52. Bush, et al. (2005). Respiratory management of the infant with type 1 spinal muscular atrophy.
  53. Praitis, et al. (2005). SMA-1 spectrin has essential roles in epithelial cell sheet morphogenesis in C. elegans.
  54. Swoboda, et al. (2005). Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.
  55. Verslype, et al. (2005). Diagnosis and treatment of autoimmune hepatitis at age 65 and older.
  56. Kesari, et al. (2005). Prenatal diagnosis of spinal muscular atrophy: Indian scenario.
  57. Grzeschik, et al. (2005). Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
  58. Lopez-Pison, et al. (2005). [Hereditary neuromuscular diseases in paediatrics. Our experience over the last 14 years.].
  59. Diers, et al. (2005). The ultrastructure of peripheral nerve, motor end-plate and skeletal muscle in patients suffering from spinal muscular atrophy with respiratory distress type 1 (SMARD1).
  60. De Groot & De Witte (2005). Physical complaints in ageing persons with spinal muscular atrophy.
  61. NMDA receptor antagnonists
  62. New Tools Available to Educate Carolinas about Often Misunderstood Disease - ALS
  63. Novartis FTY720 in trial stage III
  64. Herbal Supplement for AD
  65. ALS Chatroom & Forum Events Calendar, NEW
  66. Outcomes of a computer-based cognitive rehabilitation program in AD
  67. Cognitive rehabilitation for Alzheimer disease--the learning therapy
  68. National Registry for Amyotrophic Lateral Sclerosis [ Lou Gehrig
  69. A better tool to study role of iron in Alzheimer’s, Parkinson’s
  70. hello pals n cals
  71. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease
  72. john is 32
  73. Predicting Dementia
  74. Researchers Identify First Compound To Block Progression Of Alzheimer's Disease
  75. New Test for Lou Gehrig's Disease
  76. Quantification of {alpha}-Synuclein binding to lipid vesicles
  77. Did you Know...
  78. Neurons, smarter than believed
  79. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
  80. Researchers reverse Parkinson's symptoms in animal models
  81. Lewy bodies in the amygdala increase risk for major depression in subjects with AD
  82. Excessive daytime sleepiness in Parkinson's disease
  83. Breakthrough offers new tool for studying degenerative disease
  84. Compounds Show Potential to Repair Central Nervous System Cells After Injury
  85. Nerve fibers need specific growth factor chemical to form connections within the brai
  86. Marijuana-like Drugs Help Treatment of Nervous System Diseases
  87. Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease
  88. EuroStemCell one step closer to helping MD sufferers walk again
  89. New nerve cells in diseased brain
  90. Worldwide Parkinson's cases will double in next 25 years
  91. Human trials of oral vaccine for Alzheimer's planned in Japan
  92. Alzheimer's disease-ibuprofen effective?
  93. Newborn neurons like to hang with the 'in' crowd
  94. Intensive Treadill Training and Parkinson's
  95. Incremental Treadmill Trainin g and Parkinson's
  96. Vaccine Induced Demyelination
  97. Vaccine Adverse Event Reporting System
  98. ALS Pilot Study of G-CSF
  99. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis.
  100. Cellular Therapy in ALS
  101. Stem cells and neurodegenerative diseases.
  102. Physical Activity and Neuroprotection in ALS
  103. Resistance Exercise and ALS
  104. Pilot study of G-CSF mobilized peripheral blood stem cells in ALS
  105. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis.
  106. Accumulation of chondroitin sulfate proteoglycans in the microenvironment
  107. Behavior of neural stem cells in the Alzheimer brain
  108. ABCA2 as a therapeutic target in cancer and nervous system disorders.
  109. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders.
  110. Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise
  111. Old friends in new constellations: G-CSF, GM-CSF, and EPO
  112. Transgenic tomatoes expressing human beta-amyloid for use as a vaccine
  113. The amyloid precursor protein intracellular domain (AICD) as modulator
  114. Protective effect of quercetin in primary neurons
  115. The emerging role of docosahexaenoic acid in neuroinflammation
  116. Alzheimer's Disease Prevalence can be Lowered with Non-Invasive Testing
  117. The Damage Signals Hypothesis of Alzheimer's Disease Pathogenesis.
  118. Frontiers in the surgical treatment of Parkinson's disease.
  119. Noggin enhances dopamine neuron production
  120. Disease-specific induced pluripotent stem cells.
  121. Regenerative effect of neural-induced human mesenchymal stromal cells in Parkinsons
  122. Is it too soon for mesenchymal stem cell trials in people with ALS?
  123. What happens to a damaged spinal cord?
  124. Exercise training acts as a therapeutic sstrategy for AD
  125. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of ALS
  126. ALS research and hESC
  127. Future of cell and gene therapies for Parkinson's disease.
  128. A novel cell transplantation protocol and its application to an ALS mouse model.
  129. Human mesenchymal stem cell transplantation in ALS mouse model
  130. Human embryonic stem cell-derived motor neurons and ALS
  131. Mitochondrial dysfunction and ALS
  132. Induced pluripotent stem cells from a spinal muscular atrophy patient.
  133. Stem-cell transplantation into the frontal motor cortex in ALS
  134. From the basics to application of cell therapy
  135. Article: Mesenchymal Stem Cells and ALS
  136. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis
  137. Parkinson's disease patient-derived induced pluripotent stem cells
  138. Parkinson's patient-derived induced PSC's free of viral reprogramming factors
  139. Protective effects of neurotrophic factor secreting cells in a rat model of Parkinson
  140. comprehensive treatments for ALS in conjunction with growth factors
  141. Amyotrophic lateral sclerosis: A 40-year personal perspective
  142. From the basics to application of cell therapy
  143. Review of Lithium Effects on Brain and Blood.
  144. Stem Cell-Derived Motor Neurons
  145. Recombinant human granulocyte-colony stimulating factor for treating ALS
  146. Adult stem cell transplantation in autoimmune disease.
  147. Autologous neural stem cell transplantation: A new treatment option for Parkinson's
  148. Intrathecal transplantation of human neural stem cells in ALS
  149. Intrathecal transplantation of human neural stem cells overexpressing VEGF for ALS
  150. Adult neurotrophic factor-secreting stem cells: a potential novel therapy Parkinsons
  151. (ALS): three letters that change the people's life. Forever
  152. Stem cells in amyotrophic lateral sclerosis: state of the art.
  153. Transient Recovery in Rat Model ALS using transplantation of mouse motor neurons
  154. Motoneuron transplantation rescues the phenotype of Spinal Muscle Atrophy type 1
  155. Adult Neurogenesis, Neural Stem cells and Alzheimer's Disease
  156. RNAi Applications in Therapy Development for Neurodegenerative Disease.
  157. Molecular & cellular determinants for generating ES-cell derived dopamine neurons
  158. Embryonic stem cell & endhaced recovery in Parkinsonian mice
  159. Cells therapy for Parkinson's disease--so close and so far away.
  160. Human trials for neurodegenerative disease.
  161. Neurogenesis in mouse models of Alzheimer's disease.
  162. Mild hypoxia enhances proliferation and multipotency of human neural stem cells.
  163. Exercise exerts neuroprotective effects on Parkinson's disease model of rats.
  164. Production Process for Stem Cell Based Therapeutic Implants
  165. Metalloproteinase alterations in the bone marrow of ALS patients.
  166. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for ALS
  167. TAR DNA-binding protein 43 in neurodegenerative disease.
  168. Inhibition of calpain prevents NMDA-induced cell death
  169. Aberrant RNA processing events in neurological disorders.
  170. The biology and pathology of the familial Parkinson's disease protein LRRK2.
  171. Mitochondrial therapies for Parkinson's disease.
  172. Glutamate receptors, neurotoxicity and neurodegeneration.
  173. Autophagy: cellular and molecular mechanisms.
  174. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatments
  175. Clinical trials in CNS
  176. Safety and efficacy of lithium in combination with riluzole for treatment of ALS
  177. Neurological manifestations of antiphospholipid syndrome.
  178. Distribution/differentiation/survival of intravenously administered stem cells in ALS
  179. Cellular Repair in the Parkinsonian Nonhuman Primate Brain
  180. Stem cells in ALS:motor neuron protection or replacement?
  181. Involvement of immune response in the pathogenesis of ALS
  182. Gene therapy in hemiparkinsonian rhesus monkeys
  183. Open-labeled study of unilateral autologous mSC in PD
  184. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases.
  185. Stem cells and the ALS neurologist.
  186. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?
  187. Implications for cell-based therapies in Parkinson s disease.
  188. Towards stem cell replacement therapies for Parkinson's disease.
  189. Cellular repair in the parkinsonian nonhuman primate brain.
  190. Systemic transplantation of c-kit+ cells and ALS
  191. Neurogenic Drugs and Compounds.
  192. Huntington's disease protein results in apoptotic neurons in cloned transgenic pigs
  193. Functional neural stem cell isolation from brains of adult mutant (ALS) mice
  194. Systemic transplantation of c-kit cells exerts therapeutic effect in a model of ALS
  195. Differentiated Parkinson patient-derived induced pluripotent stem cells
  196. Safety and immunological effects of mesenchymal stem cell transplantation in MS & ALS
  197. Research Advances in Amyotrophic Lateral Sclerosis, 2009 to 2010.
  198. Cell therapy in amyotrophic lateral sclerosis: science and controversy.
  199. Brain and spinal cord affected by ALS: MSC & NSC
  200. Neuronal degeneration in striatal transplants and Huntington's disease
  201. Cervical intraspinal stem cell therapy: assessment of surgical risks in minipigs
  202. BMSCs can improve the motor function of a Huntington's disease
  203. Emerging Restorative Treatments for Parkinson's Disease
  204. Stem Cell Therapy for Alzheimer's Disease.
  205. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of PD
  206. Cycling With Functional Electrical Stimulation in an Adult With Spastic Diplegic CP
  207. Links between Thyroid disease and neurological conditions
  208. Optimization of immunosuppressive therapy for spinal grafting of human spinal SC
  209. Activation of interferon signaling pathways in spinal cord astrocytes
  210. Stem cells therapy in amyotrophic lateral sclerosis treatment. A critical view.
  211. Future therapeutical strategies dictated by pre-clinical evidence in ALS.
  212. Neural stem cell-mediated therapy for rare brain diseases
  213. Transplantation of neuronal-primed human bone marrow mesenchymal stem cells
  214. Protein-based human iPS cells efficiently generate functional dopamine neurons
  215. Functional integration of grafted neural stem cell-derived dopaminergic neurons
  216. Intramedullary spinal cord implantation of human CD34(+) in ALS
  217. Enhancing CNS repair in neurological disease
  218. Feasibility of intensive mobility training to improve gait
  219. Induced pluripotent stem cells in the study of neurological diseases.
  220. Stem cell technology for neurodegenerative diseases.
  221. Cell replacement therapy for Parkinson's disease: how close are we to the clinic?
  222. Autologous Neural Stem Cell Treatment Combined With T-Cell Vaccination for ALS
  223. Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function
  224. Bilateral transplantation of allogenic adult BM-MSCs in PD
  225. Groundbreaking Alzheimer’s Vaccine Could Cut Cases By Half
  226. Stem Cells to Improve Parkinson's Research
  227. Efficient differentiation of mouse embryonic stem cells into motor neurons.
  228. Generation of Induced Pluripotent Stem Cells from Patients with chronic diseases
  229. Intraspinal Stem Cell Transplantation in ALS: A Phase I Safety Trial
  230. Scientists aim to start stem cell therapy of Alzheimer’s by 2016
  231. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis
  232. Neural progenitors derived from human induced pluripotent stem cells in ALS
  233. Neural stem cell-based treatment for neurodegenerative diseases.